Latest News

05 November 2019

 

IMBiotechnologies Ltd. Expands Approval for EkobiTM Embolization Microspheres to Include Treatment of Uterine Fibroids

 

EkobiTM Embolization Microspheres, a novel embolization medical device has received Health Canada approval for the treatment of uterine fibroids, a significant women’s health issue.

 

IMBiotechnologies Ltd. (“IMB” or the “Company”) today announced that it has received approval from Heath Canada to expand the indications of its lead product, Ekobiä Embolization Microspheres (“Ekobi”), to include treatment of uterine fibroids.

 

Uterine fibroids are a significant women’s health issue; by the age of 50, 70% of women will develop uterine fibroids; up to 50% of uterine fibroids are symptomatic requiring treatment.  Symptoms include abnormal uterine bleeding, pelvic pressure and pain, infertility, recurrent pregnancy loss, and a significant reduction in a woman’s quality of life.  Ekobi is a patented “first-in-class” embolic therapeutic medical device that provides women with an alternative to traditional surgical treatments, such as hysterectomy (removal of the uterus) or myomectomy (removal of part of the uterus).

 

“Uterine fibroids can have a major impact on a woman’s physical and social activities,” said Michael Stewart, CEO of IMB.  “We are pleased to offer physicians a biodegradable and non-surgical treatment option for symptomatic uterine fibroids.”

 

Clinical studies have established safety and efficacy of Ekobi™ microspheres and with this approval, Ekobi™ microspheres are now indicated for the treatment of hypervascularized tumors, uterine fibroids, and enlarged prostates caused by benign prostatic hyperplasia (“BPH”). Using a minimally invasive technique called embolotherapy, Ekobi™ microspheres selectively block the blood vessels that feed a target tissue, starving it of oxygen and nutrients.  An important advantage of Ekobi is that after providing a therapeutic benefit, Ekobi™ microspheres biodegrade and are completely eliminated from the body.  In addition, Ekobi can be easily seen in the body using minimally invasive ultrasound.  Ekobi is the first, and only, biodegradable embolic agent detectable by ultrasound.

 

EkobiTM Embolization Microspheres has also received US FDA clearance for the treatment of unresectable/inoperable hypervascularized tumors.

 

About Ekobiä Embolization Microspheres

Ekobi is a first-in-class biodegradable embolic agent that is detectable by ultrasound. It is a class II medical device cleared in the USA for the treatment of unresectable/inoperable hypervascularized tumors.  In Canada, it is a class IV medical device approved for the treatment of hypervascularized tumors, uterine fibroids and enlarged prostates due to BPH.

 

About Embolotherapy

Embolotherapy works by reducing or eliminating the blood supply to target tissues. The procedure is performed by injecting embolic agents through a catheter into the blood vessels that feed a target tissue. By selectively blocking the tissue’s blood supply, the target tissue is either destroyed or devitalized, resulting in therapeutic benefit.

 

About IMBiotechnologies Ltd.

IMBiotechnologies Ltd. is a privately held Canadian medical device company located in Edmonton, Alberta, focused on the commercialization of medical products in the area of embolotherapy.

 

 

This press release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company, may ultimately prove to be incorrect. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law.

 

For More Information Please Contact:

 

Kelly Mottet

Director of Marketing and Business Development

kmottet@imbiotechnologies.com

(780) 233-4294

www.imbiotechnologies.com

20 March 2019

 

IMBiotechnologies Ltd Announces Presentation at 2019 Society of Interventional Radiology Annual Meeting (Austin, Texas)

 

Edmonton, Alberta, Canada – IMBiotechnologies Ltd today announced that an oral presentation regarding the use of its lead product, EkobiTM Embolization Microspheres (OCL 503), for treatment of benign prostatic hypertrophy (BPH).  Dr. Richard Owen, lead investigator of the clinical study conducted at the University of Alberta Hospital, will be presenting the results of an open label pilot study.  The presentation entitled “Prostate Artery Embolization using OCL 503 (a biodegradable microsphere), an open label pilot study” will be given by Dr. Owen on Sunday, March 23rd, 2019.

 

About EkobiTM

Ekobi is a first-in-class biodegradable embolic agent that is detectable by ultrasound. It is a class II medical device cleared in the USA for the treatment of unresectable/inoperable hypervascularized tumors.  In Canada, it is cleared as a class IV medical device for the treatment of hypervascularized tumors and benign prostatic hypertrophy/hyperplasia.

 

About IMBiotechnologies Ltd.

IMBiotechnologies Ltd. is a privately held Canadian medical device company located in Edmonton, Alberta, focused on the commercialization of medical products in the area embolotherapy.

 

 

For More Information Please Contact:

 

Kelly Mottet

Director of Marketing and Business Development

kmottet@imbiotechnologies.com

(780) 233-4294

www.imbiotechnologies.com

 

21 November 2018

 

IMBiotechnologies Ltd. receives Health Canada Approval for a New Biodegradable Embolic Agent

 

Edmonton, Canada – 21 November 2018 The EkobiTM product is a patented “first-in-class” embolic therapeutic medical device that provides an alternative to surgery.  EkobiTM is the first and only biodegradable embolic agent detectable by ultrasound.

 

EkobiTM microspheres selectively block the blood vessels that feed a target tissue, starving it of oxygen and nutrients.  The advantage of Ekobiä is that after providing a therapeutic benefit, EkobiTM microspheres biodegrade and are completely eliminated from the body.  Additionally, Ekobiä can be easily seen in the body using minimally invasive ultrasound. 

 

EkobiTM has already received US FDA clearance for the treatment of unresectable/inoperable hypervascularized tumors. The Health Canada approval further expands IMB’s portfolio of approved indications for its lead product.

 

“We are pleased that Health Canada has issued a medical device license for our product.  EkobiTM provides physicians with a new option to treat patients with hypervascularized tumors, and men with enlarged prostates caused by benign prostatic hyperplasia,” stated Michael Stewart, CEO of IMB.  “This approval underscores IMB’s commitment developing and manufacturing safe and effective products, while providing economic value to healthcare consumers and providers.”

 

The development and commercialization of EkobiTM microspheres was made possible, in part, by IMB accessing the Alberta innovation network.  A clinical study in patients with BPH was conducted at the University of Alberta and was supported, in part, by funding from Alberta Innovates.  The clinical study which evaluated the safety and effectiveness of EkobiTM was integral in achieving Health Canada approval.

 

“Innovations like this take considerable time and investment,” says Rollie Dykstra, Vice President, Investments at Alberta Innovates. “We know that with the right support at the right time companies like IMBiotechnologies Ltd. succeed. We congratulate them on achieving this tremendous milestone. It’s not only good for Albertans but also for people around the world.”

 

About Ekobiä

Ekobi is a first-in-class biodegradable embolic agent that is detectable by ultrasound. It is a class II medical device cleared in the USA for the treatment of unresectable/inoperable hypervascularized tumors.  In Canada, it is cleared as a class IV medical device for the treatment of hypervascularized tumors and benign prostatic hypertrophy/hyperplasia.

 

About IMBiotechnologies Ltd.

IMBiotechnologies Ltd. is a privately held Canadian medical device company located in Edmonton, Alberta, focused on the commercialization of medical products in the area embolotherapy.

 

About Alberta Innovates

Alberta Innovates invests in research, innovation and entrepreneurship to drive provincial economic growth and diversity. We ignite the power of innovation through our work with researchers, industry and entrepreneurs to move Alberta to a lower-carbon future, enhance the responsible use of land and water, and contribute to the improved health and well-being of Albertans.

Alberta Innovates provides technical expertise, entrepreneurial advice and support, opportunities for partnerships, and funding to advance the best ideas. We support a broad range of research and innovation activity – from discovery to use. Collaboration is at the heart of what we do – bringing together bright minds and great ideas to drive innovation. Find out more at albertainnovates.ca

 

About Embolotherapy

Embolotherapy works by reducing or eliminating the blood supply to target tissues. The procedure is performed by injecting embolic agents through a catheter into the blood vessels that feed the target tissue. By selectively blocking the tissue’s blood supply, the target tissue is either destroyed or devitalized, resulting in therapeutic benefit.
 

This press release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company, may ultimately prove to be incorrect. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law.

 

For More Information Please Contact:

 

Kelly Mottet

Director of Marketing and Business Development

kmottet@imbiotechnologies.com

(780) 233-4294

www.imbiotechnologies.com

 

15 November 2018

 

IMBiotechnologies announces rebranding of Embolotherapy Product from Occlusin® to EkobiTM

 

EDMONTON, ALBERTA, CANADA - IMBiotechnologies Ltd (“IMB”), an Edmonton-based medical device company, today announced the rebranding of the company’s flag-ship product Occlusin® Embolization Microspheres to EkobiTM Embolization Microspheres.

 

Mike Stewart, Chief Executive Officer at IMB, said “This rebranding reflects the unique characteristics of IMB’s lead product.  Not only are EkobiTM microspheres biodegradable, they are also detectable using ultrasound.  The name EkobiTM reflects these key properties.”

 

EkobiTM microspheres block the blood vessel(s) that feed a target tissue, starving it of oxygen and nutrients resulting in a therapeutic benefit.  EkobiTM microspheres have received medical device clearance in the USA for the treatment of unresectable/inoperable hypervascularized tumors.

 

About IMBiotechnologies Ltd.

IMBiotechnologies Ltd. is a privately held Canadian medical device company located in Edmonton, Alberta, focused on the commercialization of medical products in the area embolotherapy.

 

About Embolotherapy

Embolotherapy works by reducing or eliminating the blood supply to target tissues. The procedure is performed by injecting embolic agents through a catheter into the blood vessels that feed the target tissue. By selectively blocking the tissue’s blood supply, the target tissue is either destroyed or devitalized, resulting in therapeutic benefit.

 

FOR FURTHER INFORMATION PLEASE CONTACT:

 

Kelly Mottet

Director of Marketing and Business Development

kmottet@imbiotechnologies.com

(780) 233-4294

Global News Health Matters Coverage of Heath Canada Approval Announcement:

 

https://globalnews.ca/video/rd/1377560643736/?jwsource=cl

19 September 2018

 

IMBiotechnologies Ltd Announces Presentation at the 2018 Cardiovascular and Interventional Radiological Society of Europe Annual Meeting (Lisbon, Portugal)

 

EDMONTON, ALBERTA, CANADA - IMBiotechnologies Ltd today announced that an oral presentation regarding the use of its lead product, Occlusin® 500 Embolization Microspheres (Occlusin 500), in benign prostatic hypertrophy (BPH) patients will be presented at the 2018 Cardiovascular and Interventional Radiological Society of Europe (CIRSE) annual meeting.  Dr. Richard Owen, lead investigator of the clinical study conducted at the University of Alberta Hospital, will be presenting qualitative data assessing prostate tissue and Occlusin 500 using ultrasound in patients after prostatic artery embolization. The presentation entitled “Ultrasound detection of a biodegradable embolic microsphere after prostatic artery embolization” and will be given by Dr. Owen on Saturday, September 22nd.

 

About Occlusin 500

Occlusin 500 is a first-in-class biodegradable embolic agent that is detectable by ultrasound.  It is a class II medical device cleared in the USA for the treatment of unresectable/inoperable hypervascularized tumors.  IMBiotechnologies is currently seeking Health Canada approval for Occlusin 500.

 

About IMBiotechnologies Ltd.

IMBiotechnologies is a privately held Canadian medical device company located in Edmonton, Alberta focused on the commercialization of medical products in the area embolotherapy. 

 

About Embolotherapy

Embolotherapy works by reducing or eliminating the blood supply to target tissues.  The procedure is performed by injecting embolic agents through a catheter into the blood vessels that feed the target tissue.  By selectively blocking the tissue’s blood supply, the target tissue is either destroyed or devitalized, resulting in therapeutic benefit.

 

 

This press release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company, may ultimately prove to be incorrect. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law.

 

FOR FURTHER INFORMATION PLEASE CONTACT:

 

Kelly Mottet

Director of Marketing and Business Development

kmottet@imbiotechnologies.com

(780) 233-4294

Print Print | Sitemap
© IMBIOTECHNOLOGIES LTD.